Efficacy of novel recombinant fowlpox vaccine against recent Mexican H7N3 highly pathogenic avian influenza virus. Issue 16 (10th April 2019)
- Record Type:
- Journal Article
- Title:
- Efficacy of novel recombinant fowlpox vaccine against recent Mexican H7N3 highly pathogenic avian influenza virus. Issue 16 (10th April 2019)
- Main Title:
- Efficacy of novel recombinant fowlpox vaccine against recent Mexican H7N3 highly pathogenic avian influenza virus
- Authors:
- Criado, Miria Ferreira
Bertran, Kateri
Lee, Dong-Hun
Killmaster, Lindsay
Stephens, Christopher B.
Spackman, Erica
Sa e Silva, Mariana
Atkins, Emily
Mebatsion, Teshome
Widener, Justin
Pritchard, Nikki
King, Hallie
Swayne, David E. - Abstract:
- Highlights: rFPV-H7/3002 vaccine protected chickens against challenge Mexican 2015 H7N3 HPAIV. rFPV-H7/2155 vaccine protects against the 2012 outbreak virus but not 2015 H7N3 HPAIV. 2015 Mexican H7N3 HPAIV have gained additional N-glycosylation sites on the HA. The importance of updating vaccines for long-term effective control of H7 HPAIV. Abstract: Since 2012, H7N3 highly pathogenic avian influenza (HPAI) has produced negative economic and animal welfare impacts on poultry in central Mexico. In the present study, chickens were vaccinated with two different recombinant fowlpox virus vaccines (rFPV-H7/3002 with 2015 H7 hemagglutinin [HA] gene insert, and rFPV-H7/2155 with 2002 H7 HA gene insert), and were then challenged three weeks later with H7N3 HPAI virus (A/chicken/Jalisco/CPA-37905/2015). The rFPV-H7/3002 vaccine conferred 100% protection against mortality and morbidity, and significantly reduced virus shed titers from the respiratory and gastrointestinal tracts. In contrast, 100% of sham and rFPV-H7/2155 vaccinated birds shed virus at higher titers and died within 4 days. Pre- (15/20) and post- (20/20) challenge serum of birds vaccinated with rFPV-H7/3002 had antibodies detectable by hemagglutination inhibition (HI) assay using challenge virus antigen. However, only a few birds (3/20) in the rFPV-H7/2155 vaccinated group had antibodies that reacted against the challenge strain but all birds had antibodies that reacted against the homologous vaccine antigenHighlights: rFPV-H7/3002 vaccine protected chickens against challenge Mexican 2015 H7N3 HPAIV. rFPV-H7/2155 vaccine protects against the 2012 outbreak virus but not 2015 H7N3 HPAIV. 2015 Mexican H7N3 HPAIV have gained additional N-glycosylation sites on the HA. The importance of updating vaccines for long-term effective control of H7 HPAIV. Abstract: Since 2012, H7N3 highly pathogenic avian influenza (HPAI) has produced negative economic and animal welfare impacts on poultry in central Mexico. In the present study, chickens were vaccinated with two different recombinant fowlpox virus vaccines (rFPV-H7/3002 with 2015 H7 hemagglutinin [HA] gene insert, and rFPV-H7/2155 with 2002 H7 HA gene insert), and were then challenged three weeks later with H7N3 HPAI virus (A/chicken/Jalisco/CPA-37905/2015). The rFPV-H7/3002 vaccine conferred 100% protection against mortality and morbidity, and significantly reduced virus shed titers from the respiratory and gastrointestinal tracts. In contrast, 100% of sham and rFPV-H7/2155 vaccinated birds shed virus at higher titers and died within 4 days. Pre- (15/20) and post- (20/20) challenge serum of birds vaccinated with rFPV-H7/3002 had antibodies detectable by hemagglutination inhibition (HI) assay using challenge virus antigen. However, only a few birds (3/20) in the rFPV-H7/2155 vaccinated group had antibodies that reacted against the challenge strain but all birds had antibodies that reacted against the homologous vaccine antigen (A/turkey/Virginia/SEP-66/2002) (20/20). One possible explanation for differences in vaccines efficacy is the antigenic drift between circulating viruses and vaccines. Molecular analysis demonstrated that the Mexican H7N3 strains have continued to rapidly evolve since 2012. In addition, we identified in silico three potential new N-glycosylation sites on the globular head of the H7 HA of A/chicken/Jalisco/CPA-37905/2015 challenge virus, which were absent in 2012 H7N3 outbreak virus. Our results suggested that mutations in the HA antigenic sites including increased glycosylation sites, accumulated in the new circulating Mexican H7 HPAIV strains, altered the recognition of neutralizing antibodies from the older vaccine strain rFPV-H7/2155. Therefore, the protective efficacy of novel rFPV-H7/3002 against recent outbreak Mexican H7N3 HPAIV confirms the importance of frequent updating of vaccines seed strains for long-term effective control of H7 HPAI virus. … (more)
- Is Part Of:
- Vaccine. Volume 37:Issue 16(2019)
- Journal:
- Vaccine
- Issue:
- Volume 37:Issue 16(2019)
- Issue Display:
- Volume 37, Issue 16 (2019)
- Year:
- 2019
- Volume:
- 37
- Issue:
- 16
- Issue Sort Value:
- 2019-0037-0016-0000
- Page Start:
- 2232
- Page End:
- 2243
- Publication Date:
- 2019-04-10
- Subjects:
- Chickens -- High pathogenicity avian influenza -- H7N3 -- Immunity -- Recombinant fowlpox virus vaccine -- Vaccine
Jalisco/12283/2012 A/chicken/Jalisco/CPA-12283/2012 [H7N3] -- Jalisco/37905/2015 A/chicken/Jalisco/CPA-37905/2015 [H7N3] -- AP Alkaline phosphatase -- ABSL-2 Animal biosafety level 2 -- ABSL-3E Animal biosafety level 3 enhanced -- AIV Avian influenza viruses -- CL Cloacal swabs -- dpc Days post-challenge -- DI Defective interfering -- ECE Embryonating chicken eggs -- EID50 50 percent embryo infectious doses -- GMT Geometric mean titers -- HI Hemagglutination inhibition -- HA Hemagglutinin -- HPAI Highly pathogenic avian influenza -- LPAI Low pathogenicity avian influenza -- MDT Mean death time -- NA Neuraminidase -- OP Oropharyngeal swabs -- qRRT-PCR Quantitative real-time RT-PCR -- SDS-PAGE SDS-polyacrylamide gel electrophoresis -- SEPRL Southeast Poultry Research Laboratory -- SPF Specific-pathogen-free -- SQ Subcutaneous -- TBST Tris-buffered saline with Tween 20 -- WL White Leghorn
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0264410X ↗
http://www.clinicalkey.com/dura/browse/journalIssue/0264410X ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0264410X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.vaccine.2019.03.009 ↗
- Languages:
- English
- ISSNs:
- 0264-410X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9138.628000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 16418.xml